A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Chronic Spontaneous Urticaria

In brief

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002) in adult subjects with H-1 antihistamine refractory chronic spontaneous urticaria. Subjects who complete the randomized, double-blind, placebo-controlled treatment period may have the option to enroll in an open-label extension period and receive up to 6 doses of subcutaneous lirentelimab.

Key facts

Study ID

NCT05528861

Run by

Allakos Inc.

People needed

127

Starts

2022-10-26

Expected to finish

2024-04-18

Last updated by the study team

2024-09-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Allakos Investigational Site 227-068 — Cullman, Alabama, United States
• Allakos Investigational Site 227-014 — Phoenix, Arizona, United States
• Allakos Investigational Site 227-023 — Scottsdale, Arizona, United States
• Allakos Investigational Site 227-058 — Bakersfield, California, United States
• Allakos Investigational Site 227-026 — Los Angeles, California, United States
• Allakos Investigational Site 227-009 — Los Angeles, California, United States
• Allakos Investigational Site 227-011 — Mission Viejo, California, United States
• Allakos Investigational Site 227-021 — Santa Monica, California, United States
• Allakos Investigational Site 227-031 — Upland, California, United States
• Allakos Investigational Site 227-006 — Colorado Springs, Colorado, United States
• Allakos Investigational Site 227-036 — Jacksonville, Florida, United States
• Allakos Investigational Site 227-062 — Miami, Florida, United States
• Allakos Investigational Site 227-041 — Sarasota, Florida, United States
• Allakos Investigational Site 227-067 — Tampa, Florida, United States
• Allakos Investigational Site 227-005 — Tampa, Florida, United States
• Allakos Investigational Site 227-018 — Columbus, Georgia, United States
• Allakos Investigational Site 227-045 — Boise, Idaho, United States
• Allakos Investigational Site 227-045 — Normal, Illinois, United States
• Allakos Investigational Site 227-057 — River Forest, Illinois, United States
• Allakos Investigational Site 227-074 — Plainfield, Indiana, United States
• Allakos Investigational Site 227-047 — Overland Park, Kansas, United States
• Allakos Investigational Site 227-051 — Lexington, Kentucky, United States
• Allakos Investigational Site 227-019 — Baltimore, Maryland, United States
• Allakos Investigational Site 227-012 — Towson, Maryland, United States
• Allakos Investigational Site 227-024 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.